These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1269 related articles for article (PubMed ID: 36301821)
1. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study. Hensley KS; Jongkees MJ; Geers D; GeurtsvanKessel CH; Mueller YM; Dalm VASH; Papageorgiou G; Steggink H; Gorska A; Bogers S; den Hollander JG; Bierman WFW; Gelinck LBS; Schippers EF; Ammerlaan HSM; van der Valk M; van Vonderen MGA; Delsing CE; Gisolf EH; Bruns AHW; Lauw FN; Berrevoets MAH; Sigaloff KCE; Soetekouw R; Branger J; de Mast Q; Lammers AJJ; Lowe SH; de Vries RD; Katsikis PD; Rijnders BJA; Brinkman K; Roukens AHE; Rokx C PLoS Med; 2022 Oct; 19(10):e1003979. PubMed ID: 36301821 [TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming. Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Geers D; Schmitz KS; Garcia Garrido HM; Koopmans MPG; Dalm VASH; Kootstra NA; Huckriede ALW; Lafeber M; van Baarle D; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM; N Engl J Med; 2022 Mar; 386(10):951-963. PubMed ID: 35045226 [TBL] [Abstract][Full Text] [Related]
3. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Munro APS; Feng S; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kanji N; Libri V; Llewelyn MJ; McGregor AC; Maallah M; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Bawa T; Saralaya D; Sharma S; Sheridan R; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN; Lancet Infect Dis; 2022 Aug; 22(8):1131-1141. PubMed ID: 35550261 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary Vaccination. Jongkees MJ; Geers D; Hensley KS; Huisman W; GeurtsvanKessel CH; Bogers S; Gommers L; Papageorgiou G; Jochems SP; den Hollander JG; Schippers EF; Ammerlaan HSM; Bierman WFW; van der Valk M; Berrevoets MAH; Soetekouw R; Langebeek N; Bruns AHW; Leyten EMS; Sigaloff KCE; van Vonderen MGA; Delsing CE; Branger J; Katsikis PD; Mueller YM; de Vries RD; Rijnders BJA; Brinkman K; Rokx C; Roukens AHE J Infect Dis; 2023 Mar; 227(5):651-662. PubMed ID: 36402141 [TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Frater J; Ewer KJ; Ogbe A; Pace M; Adele S; Adland E; Alagaratnam J; Aley PK; Ali M; Ansari MA; Bara A; Bittaye M; Broadhead S; Brown A; Brown H; Cappuccini F; Cooney E; Dejnirattisai W; Dold C; Fairhead C; Fok H; Folegatti PM; Fowler J; Gibbs C; Goodman AL; Jenkin D; Jones M; Makinson R; Marchevsky NG; Mujadidi YF; Nguyen H; Parolini L; Petersen C; Plested E; Pollock KM; Ramasamy MN; Rhead S; Robinson H; Robinson N; Rongkard P; Ryan F; Serrano S; Tipoe T; Voysey M; Waters A; Zacharopoulou P; Barnes E; Dunachie S; Goulder P; Klenerman P; Screaton GR; Winston A; Hill AVS; Gilbert SC; Pollard AJ; Fidler S; Fox J; Lambe T; Lancet HIV; 2021 Aug; 8(8):e474-e485. PubMed ID: 34153264 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial. Tan NH; Geers D; Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Bogers S; van Dijk LLA; Gommers L; van Leeuwen LPM; Boerma A; Nijhof SH; van Dort KA; Koopmans MPG; Dalm VASH; Lafeber M; Kootstra NA; Huckriede ALW; van Baarle D; Zaeck LM; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM; Lancet Infect Dis; 2023 Aug; 23(8):901-913. PubMed ID: 37088096 [TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Munro APS; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Gokani K; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kwok J; Lambe T; Libri V; Llewelyn MJ; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Murira J; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Salkeld J; Saralaya D; Sharma S; Sheridan R; Sturdy A; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN; Lancet; 2021 Dec; 398(10318):2258-2276. PubMed ID: 34863358 [TBL] [Abstract][Full Text] [Related]
8. Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count. Antinori A; Cicalini S; Meschi S; Bordoni V; Lorenzini P; Vergori A; Lanini S; De Pascale L; Matusali G; Mariotti D; Cozzi Lepri A; Gallì P; Pinnetti C; Gagliardini R; Mazzotta V; Mastrorosa I; Grisetti S; Colavita F; Cimini E; Grilli E; Bellagamba R; Lapa D; Sacchi A; Marani A; Cerini C; Candela C; Fusto M; Puro V; Castilletti C; Agrati C; Girardi E; Vaia F; Clin Infect Dis; 2022 Aug; 75(1):e552-e563. PubMed ID: 35366316 [TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Madhi SA; Koen AL; Izu A; Fairlie L; Cutland CL; Baillie V; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Aley PK; Bhikha S; Hermanus T; Horne E; Jose A; Kgagudi P; Lambe T; Masenya M; Masilela M; Mkhize N; Moultrie A; Mukendi CK; Moyo-Gwete T; Nana AJ; Nzimande A; Patel F; Rhead S; Taoushanis C; Thombrayil A; van Eck S; Voysey M; Villafana TL; Vekemans J; Gilbert SC; Pollard AJ; Moore PL; Kwatra G; Lancet HIV; 2021 Sep; 8(9):e568-e580. PubMed ID: 34416193 [TBL] [Abstract][Full Text] [Related]
10. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines. Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dunsche M; Ziemssen T; Akgün K Front Immunol; 2023; 14():1081933. PubMed ID: 37545513 [TBL] [Abstract][Full Text] [Related]
11. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Hillus D; Schwarz T; Tober-Lau P; Vanshylla K; Hastor H; Thibeault C; Jentzsch S; Helbig ET; Lippert LJ; Tscheak P; Schmidt ML; Riege J; Solarek A; von Kalle C; Dang-Heine C; Gruell H; Kopankiewicz P; Suttorp N; Drosten C; Bias H; Seybold J; ; Klein F; Kurth F; Corman VM; Sander LE Lancet Respir Med; 2021 Nov; 9(11):1255-1265. PubMed ID: 34391547 [TBL] [Abstract][Full Text] [Related]
12. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ; Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136 [TBL] [Abstract][Full Text] [Related]
13. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers. Brunner WM; Freilich D; Victory J; Krupa N; Scribani MB; Jenkins P; Lasher EG; Fink A; Shah A; Cross P; Bush V; Peek LJ; Pestano GA; Gadomski AM Int J Infect Dis; 2022 Oct; 123():183-191. PubMed ID: 36044963 [TBL] [Abstract][Full Text] [Related]
15. Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. Liu X; Munro APS; Feng S; Janani L; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dejnirattisai W; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kwok J; Libri V; Llewelyn MJ; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Serafimova T; Saralaya D; Screaton GR; Sharma S; Sheridan R; Sturdy A; Supasa P; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Cornelius V; Snape MD; Faust SN; J Infect; 2022 Jun; 84(6):795-813. PubMed ID: 35405168 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of a bivalent BA.1 COVID-19 booster vaccine in people with HIV in the Netherlands. Jongkees MJ; Tan NH; Geers D; de Vries RD; GeurtsvanKessel CH; Hensley KS; Sablerolles RSG; Bogers S; Gommers L; Blakaj B; Miranda Afonso P; Hansen BE; Rijnders BJA; Brinkman K; van der Kuy PHM; Roukens AHE; Rokx C AIDS; 2024 Jul; 38(9):1355-1365. PubMed ID: 38788210 [TBL] [Abstract][Full Text] [Related]
17. Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study. Wolff M; Charpentier P; Canals A; Vial C; Hormazábal J; Cortés J; Silva M Vaccine; 2024 Jan; 42(3):671-676. PubMed ID: 38123398 [TBL] [Abstract][Full Text] [Related]
18. Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV. Corma-Gómez A; Fernández-Fuertes M; García E; Fuentes-López A; Gómez-Ayerbe C; Rivero-Juárez A; Domínguez C; Santos M; Viñuela L; Palacios R; Real LM; Rivero A; Macías J; Pineda JA; García F Clin Microbiol Infect; 2022 Nov; 28(11):1492-1498. PubMed ID: 35640840 [TBL] [Abstract][Full Text] [Related]
19. Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV. Lv Z; Li Q; Feng Z; Zheng X; NaYin ; Yang H; Gu Q; Ying S; Qi Y; Li X; Wu R; Wu Z; Yu X; Zou N; Qin D; Wan C Int Immunopharmacol; 2022 Jan; 102():108383. PubMed ID: 34824035 [TBL] [Abstract][Full Text] [Related]
20. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study. van Gils MJ; Lavell A; van der Straten K; Appelman B; Bontjer I; Poniman M; Burger JA; Oomen M; Bouhuijs JH; van Vught LA; Slim MA; Schinkel M; Wynberg E; van Willigen HDG; Grobben M; Tejjani K; van Rijswijk J; Snitselaar JL; Caniels TG; ; Vlaar APJ; Prins M; de Jong MD; de Bree GJ; Sikkens JJ; Bomers MK; Sanders RW PLoS Med; 2022 May; 19(5):e1003991. PubMed ID: 35580156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]